SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Concord Biotech informs about record date

08 Aug 2025 Evaluate
With reference to the intimation of Board meeting submitted on August 04 2025, Concord Biotech has informed that the Board of Directors of the Company, at its meeting held today i.e. Friday, August 08, 2025, has approved Unaudited Standalone and Consolidated Financial Results for the First quarter ended on June 30, 2025. The said results were also reviewed by the Audit Committee of the Company in its meeting held on August 08, 2025. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, they enclosed the Unaudited Standalone and Consolidated Financial Results of the Company for the First quarter ended on June 30, 2025, along with the Limited Review Report with Unmodified Opinion issued by BSR & Co. LLP, the Statutory auditors. Pursuant to the Regulation 42 of SEBI Listing Regulations, the Company has fixed Wednesday, 3rd September, 2025 as ‘Record Date’ for the purpose of determining entitlement for the purpose of identifying the members entitlement to receive Dividend of Rs 10.70 per Equity Share having face value of Re 1 each fully paid-up for the financial year 2024-25. The Board Meeting commenced at 3:00 PM and concluded at 4:00 PM.

The above information is a part of company’s filings submitted to BSE.

Concord Biotech Share Price

1316.55 -25.45 (-1.90%)
19-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1837.15
Dr. Reddys Lab 1271.55
Cipla 1353.85
Zydus Lifesciences 1070.90
Lupin 2351.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: